Appointment of Independent Non-Executive Director

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce the appointment of Ketan Patel to the Board, as an independent Non-Executive Director. The appointment is with immediate effect.

Ketan is an experienced investment professional and brings extensive expertise in financial markets with a focus in the UK healthcare and life science sectors. He has been a long-term investor in UK markets, as an analyst and Fund Manager, running institutional, retail and charity mandates. Ketan started his career at JP Morgan, before moving to Insight Investment where he was a global Pharmaceutical and Healthcare analyst and spent over 20 years at EdenTree Investment Management where he was responsible for UK equity and global equity income strategies delivering consistent upper quartile performance.

Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes,

Ketan is a CFA Charterholder. He also holds an MSc Economic History, from London School of Economics, MSc Geography from King’s College London and BA (Hons) History and Geography from Queen Mary University, London.

Tim McCarthy, Chief Executive Officer of ImmuPharma, said:

“We are extremely pleased to welcome Ketan to our Board. His extensive expertise in the global pharmaceutical and life science sectors and strong investment acumen will be invaluable to ImmuPharma.

Importantly, Ketan’s appointment, at this time, brings a unique perspective to the Board, as we concentrate on future strategic partnerships and commercial deals across our product portfolio and in particular, our lead auto-immune platform technology, P140. In addition, Ketan’s investment management experience will greatly assist us in expanding our institutional shareholder base.”

Ketan Patel, commented:

“After nearly three decades of investing in mid and small cap UK companies with a focus on healthcare and life science, I am delighted to be joining the ImmuPharma team at this pivotal stage of their journey and look forward to contributing to the future success of the business.”

To download form Click here